Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT03378414
PHASE2

Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-SA) for Patients With Spinocerebellar Ataxia

Sponsor: Sclnow Biotechnology Co., Ltd.

View on ClinicalTrials.gov

Summary

The purpose of this study is verify the safety and efficacy of Human Umbilical Cord Mesenchymal Stem Cells (UC-MSC) therapy for patients with Spinocerebellar Ataxia, and in addition, explore the possible mechanisms of UC-MSC therapy in Spinocerebellar Ataxia.

Official title: A Clinical Research on the Safety/Efficacy of Umbilical Cord Mesenchymal Stem Cells Therapy for Patients With Spinocerebellar Ataxia

Key Details

Gender

All

Age Range

16 Years - 60 Years

Study Type

INTERVENTIONAL

Enrollment

45

Start Date

2025-12-31

Completion Date

2026-12-31

Last Updated

2025-12-04

Healthy Volunteers

No

Interventions

PROCEDURE

Intravenous infusion

Intravenous infusion of mesenchymal stem cells: 2 \* 10\^7 cells (30ml)

PROCEDURE

Intrathecal injection

Intrathecal injection of mesenchymal stem cells: 2 \* 10\^7 cells (1ml)

BIOLOGICAL

umbilical cord mesenchymal stem cell

Treat patients with umbilical cord mesenchymal stem cell (SCLnow 19#), the dosage based on different procedure